Evidence map›Paper›PMID 41776767›Full record

ArticleACS nano2026

Reprogramming Lesional Macrophage Homeostasis via Interferon Regulatory Factor 5 Targeted siRNA Nanoimmunotherapy for Atherosclerosis.

Zhongshan He, Yaoyao Luo, Shuping Yang, Haixing Shi, Ya-Chih Huang, Zhuoming Zhou, Shengbin Liu, Wanqin Zeng, Wei-Chieh Liu, Yongjiang Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zhongshan HeDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.ORCID 0000-0003-2108-7929
Yaoyao LuoLaboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.
Shuping YangDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.
Haixing ShiDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.
Ya-Chih HuangGenomics Research Center, Academia Sinica, Taipei 115, Taiwan.
Zhuoming ZhouCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
Shengbin LiuDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.ORCID 0000-0001-7512-4225
Wanqin ZengDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.
Wei-Chieh LiuGenomics Research Center, Academia Sinica, Taipei 115, Taiwan.
Yongjiang LiCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.ORCID 0000-0001-6882-7862
Yuting ChenDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.
Duotian QinCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
Xing DuanDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.
Xi HeDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.
Wei ChenGenomics Research Center, Academia Sinica, Taipei 115, Taiwan.ORCID 0000-0002-2909-3023
Xiangrong SongDepartment of Clinical Pharmacy, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Tianfu Jincheng Laboratory, Chengdu 610041, China.ORCID 0000-0002-2853-2696

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerotic macrophages predominantly exhibit a pro-inflammatory phenotype, driving chronic inflammatory and accelerating atherosclerotic progression. Interferon regulatory factor 5 (IRF5) is highly expressed in lesional macrophages within advanced atherosclerotic plaques, where it promotes the secretion of pro-inflammatory cytokines. However, current approaches lack an effective therapeutic strategy to specifically silence this gene in lesional macrophages for atherosclerosis treatment. This study aims to develop and evaluate a dual-targeted, siRNA-based nanotherapeutic platform that selectively acts on atherosclerosis-promoting genes in plaque macrophages, offering a potential strategy for treating atherosclerosis by reprogramming lesional macrophages. Here we designed and developed dual-targeted liposome-based nano-immunotherapeutics encapsulating small interfering RNA (siRNA) against IRF5 (siIRF5) to reprogram macrophage phenotypes within advanced plaques. In high-fat diet-fed

Indexed as

AtherosclerosisImmunotherapyInterferon Regulatory FactorsMacrophagesRNA, Small InterferingAnimalsHomeostasisHumansLiposomesMaleMiceMice, Inbred C57BLInterferon Regulatory FactorsIrf5 protein, mouseLiposomesRNA, Small Interferingatherosclerosismacrophage homeostasisnanoimmunotherapysmall interfering RNAtargeted delivery

Identifiers

PMID41776767
PMCPMC13001080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.